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Study objectives: The aim of the study was to investigate the relationship between the immediate bronchial response
to inhaled cigarette smoke [cigarette smoke bronchial reactivity (CBR)] and lung function, respiratory symptoms
and markers of allergy and inflammation.
Design, participants and measurements: This cross-sectional study included 98 smokers. Their lung function and
reversibility to inhaled terbutaline was measured. Their clinical history was obtained, an allergological examination
was done, and bronchial reactivity to methacholine and inhaled cigarette smoke was measured. Questionnaires
about respiratory symptoms, smoking history and drug usage were completed and a blood sample was obtained.
Participants were divided into three groups: with asthma, chronic bronchitis and persons without asthma or chronic
bronchitis (the respiratory healthy).
Results: Forced expiratory volume in 1sec (FEV1) residuals were independently related to the % fall in FEV1
after 12 cigarette smoke inhalations (DFEV%) in all participants (P5001), in asthmatic smokers (P5001) and in
smokers with chronic bronchitis (P5005). In smokers with asthma and chronic bronchitis FEV1 residuals
explained 51% and 13% of the variation in DFEV%, respectively, but only 8% (P5005) and 1% (N.S.) of the
variation in the methacholine bronchial reactivity. In the total population the presence of wheeze (P5001), attacks
of breathlessness (P5005) and daily expectoration (P50001) were related to higher DFEV% readings. Serum
immunonoglobulin (ES-IgE) was independently related to DFEV% in all participants (P5001), in smokers with
chronic bronchitis (P5001) and in the respiratory healthy ( 0055P501). The eosinophil blood count was, in
similar analyses, related to DFEV% in all participants (P5005) and in persons with chronic bronchitis
(0055P501).
Conclusion: Cigarette smoke bronchial reactivity was strongly associated to actual FEV1 in smokers with asthma
and bronchitis, overall to most respiratory symptoms and in smokers without asthma to S-IgE. Cigarette smoke
bronchial reactivity might be suitable to test further how cigarette smoke influences the pathophysiology of the
bronchial wall, especially in smokers with asthma.
RESPIR. MED. (2000) 94, 119±127 # 2000 HARCOURT PUBLISHERS LTDIntroduction
Cigarette smoking is a major cause of morbidity and death
(1). Smoking is the most important cause of development of
chronic bronchitis and emphysema (2,3).
The reasons for the susceptibility to the development
airflow of limitation are virtually unknown, and both
asthmatics (4) and non-asthmatics (5) may develop
respiratory insuciency even after minimal cigarette con-
sumption.Paper received 8 June 1999 and accepted 9 June 1999.
Correspondence should be addressed to: Dr Erik Juel Jensen,
Department of Respiratory Diseases, University Hospital Of
Aarhus, Noerrebrogade, Dk-8000 Aarhus C, Denmark. Fax: 45
89492110.
0954-6111/00/020119+09 $35?00/0Whether smoking causes increased bronchial reactivity
[bronchial hyper reactivity (BHR)] in histamine/metha-
choline remains controversial (6–12), and it is unclear if
atopy contributes to the development of BHR in smokers
(6,10, 12). Studies have suggested that BHR in smokers is
related to an increased loss of lung function (5,13–16).
However, studies on BHR in smokers have not given an
explanation for the accelerated lung function loss in some
smokers.
In a previous publication we described the relationship
between the immediate bronchial response to inhaled
cigarette smoke (CBR), BHR and smoking (17).
The present study was performed to investigate relation-
ships between CBR and lung function, respiratory symp-
toms and objective markers of atopy and inflammation.# 2000 HARCOURT PUBLISHERS LTD
120 E. J. JENSEN ET AL.Population and methods
Ninety-eight smokers were randomly selected from among
198 persons who participated in a smoking cessation
programme. Presence of asthma, type 1 allergy, chronic
bronchitis, or chronic obstructive airway disease were not
exclusion criterion, but subjects were otherwise healthy and
had had no airway infections within the 2 weeks before
entering this study. Demographic data for those enrolled in
this study are listed in Table 1.
METHACHOLINE BRONCHIAL
CHALLENGE
Participants with FEV141 had a bronchial challenge with
methacholine bromide. A Wright nebulizer driven by
compressed air at 13 bar and a flow of 5 l min71, and
with a mean output of 014 ml min71, was used for
inhalations. After an initial saline inhalation, participants
inhaled unbuered methacholine in doubling doses from
003 mg ml71 to 16 mg71 ml. The inhalation was
performed with tidal breathing for 2 min intersparsed with
5 min intervals. FEV1 was measured 30 and 90 sec after the
inhalation and the highest value selected. The challenge was
stopped if FEV1 decreased 20% or more from baseline or if
the maximum dose of 16 mg ml71 was reached. The slope
of the regression line through all datapoints (SAP) was
determined for each participant and used as an expression
of the bronchial response to methacholine, as this expres-
sion is continuous and suitable for regression analyses (11).
By natural logarithmic transformation the expression was
normally distributed, and to avoid zero a small constant
(02) was added to SAP before transformation. SAP was the
percent change in FEV1 per mg ml
71 methacholine.
Participants abstained from methylxanthines and oral b2-
agonists for 48 h and from inhaled b2-agonists and smokingTABLE 1. Demographic data according to asthma and chronic
Overall Asthma
N 98 13
VC (l) 38 (17–68) 44 (28–5
FEV1 (l) 24 (06–47) 30 (21–4
FEV1/VC 063 (03–088) 068 (060–
SAP(SE % mg71 ml71) 113 (86) 396 (16
Age (years) 49 (21–70) 36 (21–6
Sex (m/f) 53/45 7/6
Height (cm) 172 (153–193) 175 (160–1
Pack–years consumption 437 (84–76) 308 (8–4
Allergy present 7 5
Allergy in family 35 7
Asthma in family 25 7from the evening before the challenge. Inhaled long acting
b2-agonists were not used.
CIGARETTE SMOKE BRONCHIAL
CHALLENGE
An unfiltered commercial and popular brand of cigarettes
with a nicotine content of 14 mg and a tar content of 15 mg
was used. Participants were asked to smoke and inhale as
usual. Participants were requested to avoid smoking for
24 h before the challenge. Partial and maximum flow
volume curves were obtained before the challenge, and
30 sec after three, six, and 12 inhalations, and 5, 10, 15 and
30 min after the last inhalation. The avarage of three
measurements with less than 5% variation in FEV1 was
chosen as the baseline value. During challenge only one
lung function manoeuvre was possible at each measuring
point. All subjects had practised the lung function
manoeuvres and obtained a reproduceable technique.
ALLERGOLOGICAL EXAMINATIONS
All had an allergological examination with a skin prick test
(Soluprick, ALK-Laboratories, Denmark) and allergen-
specific IgE analyses (phadebas RAST, Pharmacia Diag-
nostics, Sweden). The 14 allergens included detect more
than 95% of allergies in Denmark. Participants were
considered allergic if they presented a wheal at least half
the size of the histamine response or had a specific
radioallergosorbent test (RAST) greater or equal to
035 kU l71.
BLOOD SAMPLES
Total blood white cell counts were measured on a Coulter
counter S (Coulter Electronics, Hialeah, FL, U.S.A.) Serumbronchitis [means (range)]
Bronchitis Healthy P
58 27
9) 35 (17–68) 40 (24–64) 5005
5) 21 (06–44) 29 (23–47) 50001
083) 058 (03–088) 07 (06–086) 500001
4) 426 (94) 02 (05) 500001
5) 52 (24–70) 50 (32–65) 500001
27/31 18/9 N.S.
90) 171 (160–193) 173 (159–192) N.S.




BRONCHIAL REACTIVITY TO CIGARETTE SMOKE 121samples were stored at 7208C until analysed. S-IgE was
determined using ELISA. The number of blood eosinophils
were counted in a Fuchs–Rosenthal chamber.
TOBACCO ABSTINENCE
Tobacco abstinence was controlled by carbon monoxide
(CO) in expired air (Ecolyzer CO-monitor, Hawthorne,
New York, U.S.A.) (18). Cigarette smoke bronchial
challenge was not performed in participants with a CO
concentration in expired air greater than 3 ppm.
LUNG FUNCTION MEASUREMENTS
Lung function measurements were performed on a Jaeger
Transfer screen II and included total lung volume, forced
expiratory volume in 1 s (FEV1), vital capacity (VC), forced
vital capacity (FVC), peak expiratory flow (PEF) and CO
transfer capacity (TLCO). Normal values were obtained
from (19). By means of standard residuals, FEV1 was
normally distributed and independent of height, age and
gender (20).
Participants presenting an abnormal spirometry were
given four inhalations of an aerosol containing terbutaline
05 mg per dose and asked to perform spirometry after 30
min. During methacholine bronchial challenge FEV1 was
measured on a dry wedge spirometer (Vitalograph, Buck-
ingham, U.K.).
A rolling seal spirometer (Morgan, Gillingham, U.K.)
was used for partial and maximum flow volume curves dur-
ing the cigarette smoke bronchial challenge. The lung func-
tion indices analysed were FEV1, MEF75, and FEF25–75.
The average of three measurements of each index with
variations less than 5% in FEV1 was chosen as baseline
value.
FEV1 measured with the three dierent devices were
identical.TABLE 2. Bivariate regression analyses with DFEV% as the
Analyses were done in the total population and in subgroups w
DFEV% is the percent fall in FEV1 after 12 cigarette smoke in
Population sample Independent variable
All (n98) FEV1 residuals
pack–years consumption
FEV1/VC
Asthma (n13) FEV1 residuals
pack–years consumption
FEV1/VC
Chronic bronchitis (n72) FEV1 residuals
pack–years consumption
FEV1/VC
Respiratory healthy (n13) FEV1 residuals
pack–years consumption
FEV1/VCQUESTIONNAIRES
An investigator completed in a questionnaire about the
individuals’ use of medicine, symptoms of asthma, chronic
bronchitis, hay fever, urticaria, and if their physician had
given them the diagnosis, asthma, chronic bronchitis or
asthmatic bronchitis. Presence of airway symptoms, such as
daily cough, wheeze and shortness of breath were sought
for to clarify the questionnaire recommended by the British
Committee on Research into Chronic Bronchitis.
CLASSIFICATION OF PARTICIPANTS
Asthma was considered present if a physician had given the
diagnosis asthma or asthmatic bronchitis and a 20% or
more increase in FEV1 was obtained after terbutaline
inhalation.
Chronic bronchitis was considered present if a physician
had given the diagnosis bronchitis, asthmatic bronchitis, or
asthma and a 20% increase in FEV1 was not obtained after
terbutaline inhalation, and/or they presented airway
symptoms such as daily cough and/or expectoration for
at least 3 months of a year.
They were considered as respiratory healthy if they did
not meet the criteria for asthma or chronic bronchitis and
presented a normal lung function.
SMOKING HISTORY
The participants were asked about duration of former and
actual consumption of light filter cigarettes, ordinary filter
cigarettes, unfiltered cigarettes, small cigars, cigars and pipe
tobacco. Dierent forms of tobacco products often contain
dierent concentrations of active constituents that may
serve as irritants of the airways. Tobacco consumption was
standardized according to nicotine content and, therefore,dependent variable and independent variables as indicated.
ith asthma, chronic bronchitis and in the respiratory healthy.
halations. SE = standard error
Regression coecient
(SE) Intercept P
702 (0005) 18 500001
001 (0005) 19 5005
7002 (0005) 36 500001
704 (01) 14 50005
001 (001) 20 N.S.
7002 (001) 38 N.S.
702 (01) 19 50005
001 (0006) 19 5005
7002 (0007) 35 5001
02 (02) 17 N.S.
0001 (001) 16 N.S.
01 (01) 738 N.S.
122 E. J. JENSEN ET AL.also to tar content. The nicotine and tar content of tobacco
products are usually related.
Each product was transformed into ‘standard’ cigarettes:
one light filter cigarette (nicotine content06–10 mg)2/3
standard cigarette; one ordinary filter cigarette (nicotine
content10–16 mg)1 standard cigarette; one unfiltered
cigarette (nicotine content16–24 mg) 11
3 standard
cigarette; one small cigar3 standard cigarettes; one
cigar5 standard cigarettes; one gram of pipe tobacco1
standard cigarette.
Daily cigarette consumption (DC) was the sum of all the
tobacco forms smoked at present, transformed into
standard cigarettes. Pack–years consumption (PY) was
the transformed sum of each of the tobacco forms smoked
over the years, multiplied by the number of years the
specific tobacco form had been smoked and divided by 20.
ETHICS
All participants gave their informed consent to participate.
The study was approved by the scientific ethics committee
of Aarhus county.
STATISTICS
The BMDP statistical package (21) was used in all
calculations. Ln-transformed values of the % fall from
baseline in a specific lung function index was used to
quantify the magnitude of the bronchial response to
cigarette smoke, as these numbers were normally distrib-
uted. Values are given as geometric means +1 standard
error (SE). Bivariate and multivariate linear regression
analyses were used to evaluate relationships between the
bronchial response to inhaled cigarette smoke and other
variables.
P values less than 005 were considered significant, and P
values greater than 005 and less than 01 were considered
to represent a trend.
Results
DFEV% was the mean % fall in FEV1 from baseline after
12 inhalations of an unfiltered cigarette. In the total
population DFEV% was 102+13%
CIGARETTE SMOKE AND
METHACHOLINE BRONCHIAL
REACTIVITY, LUNG FUNCTION, AND
RESPIRATORY SYMPTOMS
The multivariate regression analyses included DFEV% as
the dependent variable and FEV1 residuals, pack–years
consumption and the FEV1/VC ratio as the independent
variables. The variables FEV1/VC and FEV1 residuals were
not independent. Because of this, in the multivariate
regression analyses involving both FEV1/VC and FEV1
residuals as independent variables, FEV1/VC was not usedas a continous variable but was stratified into three strata;
FEV1/VC  06, 06FEV1/VC08 and FEV1/VC408.
Bivariate relationships between DFEV% and FEV1
residuals, FEV1/VC, and pack–years consumption are
shown in Table 3.
The multivariate regression analyses showed an indepen-
dent relationship between FEV1 residuals and DFEV% in
the total population (P5001), in smokers with asthma
(P5001) and in smokers with chronic bronchitis,
(P5005) (Table 3). FEV1 residuals independently ex-
plained 51% and 13% of the variation in DFEV% in
smokers with asthma and chronic bronchitis, respectively
(Table 3). The significant relationship between FEV1
residuals and cigarette smoke bronchial reactivity, persist-
ing after SAP from methacholine bronchial reactivity, was
added to the list of independent variables in the total
population, in asthmatics and in smokers with chronic
bronchitis (Table 4).
When SAP was used as the dependent variable and the
above independent variables were maintained, the multi-
variate regression analyses showed a significant and
independent relationship between methacholine SAP and
FEV1 residuals in the total population (P5001) and in
smokers with asthma (P5005). In the multivariate
analyses FEV1 residuals independently explained 28%,
8% and 1% of the variation of methacholine SAP in the
total population of smokers, in smokers with asthma and in
smokers with chronic bronchitis, respectively. We found no
independent relationship between FEV1 residuals and
DFEV% or methacholine SAP in smokers considered
respiratory healthy.
In the total population, persons with attacks of wheeze
(P5001), attacks of breathlessness (P5005) and chronic
sputum (P50001) had higher DFEV% readings compared
to persons without these symptoms (Table 5).
RELATIONSHIPS BETWEEN MARKERS OF
ATOPY AND INFLAMMATION AND
DFEV%
Bivariate regression analyses, including the total popula-
tion, showed that DFEV% was significantly related to the
FEV1/VC ratio, pack–years consumption, asthmatic/
bronchitic status, blood eosinophil count and S-IgE.
DFEV% was not related to the total blood leucocyte count
or allergic status (Table 6).
In the total population, multivariate regression analyses,
including the variables mentioned above and with DFEV%
as the dependent variable, showed that both S-IgE
(P5001) and the blood eosinophil count (P5005) were
independently related to DFEV% (Table 7). S-IgE and the
total blood eosinophil count explained 5% and 4%,
respectively, of the variation in DFEV% (Table 7).
The multivariate regression analyses were repeated in the
groups of asthmatics, persons with chronic bronchitis and
persons considered respiratory healthy. S-IgE was signifi-
cantly related to DFEV% in persons with chronic
bronchitis (P5001) and tended to be related to DFEV%
in persons considered respiratory healthy (0055P501)
TABLE 3. Multivariate regression analyses with DFEV% or SAP as the dependent variable and independent variables as
indicated. Analyses were performed in the total population and in subgroups of smokers as indicated. R2 is the square of the
correlation coecient from the multivariate regression analyses and P the significance of the individual variable at the 0.05%






to R2 P R2
Contribution
to R2 P
All (n=98) FEV1 residuals 018 018 P5001 028 028 5001
FEV1/VC 019 001 N.S. 033 005 5005
pack–years
consumption
022 003 0055P501 034 001 N.S.
Smokers with
asthma (n13)
FEV1 residuals 051 051 5001 008 008 5005
FEV1/VC 056 005 N.S. 046 038 5005
pack–years
consumption
060 004 N.S. 048 002 N.S.
Smokers with chronic
bronchitis (n72)
FEV1 residuals 013 013 P5005 001 001 N.S.
FEV1/VC 016 003 N.S. 032 031 N.S.
pack–years
consumption
022 006 5005 034 002 N.S.
Smokers considered
respiratory healthy (n13)
FEV1 residuals 008 008 N.S. NA NA NA
FEV1/VC 018 010 N.S. NA NA NA
pack–years
consumption
021 003 N.S. NA NA NA
TABLE 4. Multivariate regression analyses with either DFEV% or SAP as the dependent variables and independent variables
as indicated. Analyses were performed in the total population, and in subgroups of smokers with asthma or chronic
bronchitis. P is the significance of the individual independent variable at the 005% level.
Dependent variable
DFEV% SAP
Sample Independent variable P P
Total population (n98) FEV1 resdiuals 5005 5005




Smokers with asthma (n13) FEV1 residuals 5001 0055P501




Smokers with chronic bronchitis (n72) FEV1 residuals 0055P501 N.S.
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TABLE 5. DFEV% in 98 smokers with and without respiratory symptoms controlled for FEV1/VC. P1 is the dierence in
DFEV% between persons with and without the symptom and P2 the dierence in DFEV% between persons with FEV1/VC
507 and FEV1/VC407. Geometric means (1 standard error)
Symptom Present Symptom Absent P1 P2
Symptom FEV1/VC407 FEV1/VC407 FEV1/VC407 FEV1/VC407
n DFEV% n DFEV% n DFEV% n DFEV%
Attacks of wheeze 33 155 (12) 12 78 (28) 30 90 (19) 23 57517) 5001 50005
Attacks of breathlessness 34 155 (12) 17 78 (28) 24 101 (20) 18 57 (10) 5005 50005
Chronic expectoration 47 148 (11) 21 64 (13) 16 60 (13) 14 58 (27) 50001 5005
Dry cough 36 126 (19) 14 73 (12) 27 123 (21) 21 73 (12) N.S. 50005
TABLE 6. Relationship between DFEV% and serum immunoglobulin E, blood eosinophil count, total leucocyte blood count,
pack–years consumption, FEV1/VC, allergic status, and presence of asthma/bronchitis. Bivariate regression analyses with
DFEV% as the dependent variable and independent variables as indicated. SE is 1 standard error
Independent variable Regression coecients (SE) Intercept P
FEV1/VC 6.474 (21) 15 5005
Pack–years consumption 003(002) 19 5005
Serum IgE 707*1073 (03*1073) 23 5005
Blood eosinophil count 709*1073 (04*1073) 23 5005
Blood leukocyte count 706*1073 (0.5*1073) 22 N.S.
Allergic status (yes/no) 03 (03) 17 N.S.
Asthma/chronic bronchitis 703 (01) 19 0055P501
TABLE 7. Relationship between DFEV% and serum immunoglobulin E, blood eosinophil count, and total blood leucocyte
count. Multivariate regression analyses with DFEV% as the dependent variable and independent variables as indicated.
Analyses were carried out in the total population (n98). r2 is the square of the correlation coecient
Independent variable r2 increase r2 P
FEV1/VC 005 005 5005
Pack–years consumption 008 003 5005
Serum IgE 013 005 5001
Blood eosinophil count 017 004 5005
Blood leucocyte count 017 000 N.S.
Allergic status (yes/no) 018 001 N.S.
Asthma/chornic bronchitis 028 010 500001
124 E. J. JENSEN ET AL.(Table 8). The blood eosinophil count tended to be related
to DFEV% in persons with chronic bronchitis
(0055P501) (Table 8).
There were no relationships between S-IgE and pack–
years consumption in the total population, in asthmatics, or
in the respiratory healthy, but in smokers with chronic
bronchitis S-IgE was related to pack–years consumption
(r027, P5005). There was no relationship between
blood eosinophil count, pack–years consumption and
S-IgE.Discussion
This study was performed to investigate the acute
bronchial response to cigarette smoke and methacholine
inhalation, and the relationship to baseline lung function
in a population of smokers. In addition the relationship
between cigarette smoke bronchial reactivity and re-
spiratory symptoms, S-IgE, blood eosinophil count and
the total blood leucocyte count was studied. The analyses
were performed in the total population and in subgroups
TABLE 8. Relationship between DFEV% and serum immunoglobulin E, blood eosinophil count, and blood leucocyte count.
Multivariate regression analyses with DFEV% as the dependent variable and independent variables as indicated. Analyses
were performed in subgroups of persons with asthma, chronic bronchitis and persons regarded respiratory healthy. r2 is the
square of the correlation coecient
Group Independent variables r2 increase r2 P
Persons with asthma (n13) FEV1/VC 001 001 N.S.
Pack–years consumption 008 007 N.S.
Serum IgE 027 019 N.S.
Blood eosinophil count 028 001 N.S.
Leucocyte blood count 030 002 N.S.
Allergic status (yes/no) 031 001 N.S.
Persons with chronic bronchitis (n72) FEV1/VC 014 014 5001
Pack–years consumption 017 003 5005
Serum IgE 029 012 5001
Blood eosinophil count 032 003 0055P501
Blood leucocyte count 033 001 N.S.
Allergic status (yes/no) 033 000 N.S.
Respirtory healthy persons (n13) FEV1/VC 004 004 N.S.
Pack–years consumption 004 000 N.S.
Serum IgE 045 041 0055P501
Blood eosinophil count 045 000 N.S.
Blood leucocyte count 049 004 N.S.
Allergic status (yes/no) 049 000 N.S.
BRONCHIAL REACTIVITY TO CIGARETTE SMOKE 125according to the presence of asthma or chronic bron-
chitis.
The main results of the study showed that DFEV% was
independently related to baseline lung function and to most
respiratory symptoms. S-IgE was related to DFEV% in the
total population, in persons with chronic bronchitis and in
the respiratory healthy. The blood eosinophil count tended
to be related to DFEV% in smokers with chronic
bronchitis. The population was unevenly composed with
respect to asthmatics, persons with chronic bronchitis and
the respiratory healthy. The group with chronic bronchitis
was of a suitable size for performing multivariate analyses
but the groups, with asthma and good respiratory health
were small. This probably limited the possibility of showing
relationships between some of the variables in the multi-
variate analyses. Relationships between DFEV% and S-
IgE, blood eosinophil count and total blood leucocyte
count, therefore, could not be elucidated clearly in this
study regarding asthmatics and persons considered respira-
tory healthy.
Classification, with respect to asthma, was performed
according to the information provided by the participants,
supplemented with a test for reversibility in FEV1. The
classification was supported by a higher bronchial sensitiv-
ity to methacholine in smokers with asthma and chronic
bronchitis, compared to persons considered respiratory
healthy. The respiratory healthy all had negative methacho-
line challenges. Asthmatics had higher lung function than
smokers classified as having chronic bronchitis. The risk of
mis-classification of persons with type 1 allergy was very
low as the allergens used for testing covered 95% of known
inhaled allergens in Denmark.The cigarette smoke bronchial challenge was not
standardized. Results with less variability could probably
be achieved by monitoring plasma nicotine or carbon
monoxide in expired air during the challenge. In an earlier
report (17) we showed a good correlation between two
cigarette smoke bronchial challenges performed with an
interval of 1 h.
The immediate bronchial response to cigarette smoke has
been tested in several studies (22–29). However, its relation
to lung function, respiratory symptoms, or markers of
atopy and inflammation has not been investigated.
The bronchial response to methacholine/histamine in
earlier studies has explained 0–35% of the variation in
FEV1(30–33). This is consistent with the results of this
study, as the percentage of variation in the bronchial
reactivity to methacholine explained by FEV1 residuals in
the total population was within this range. The lower
percentage of variation in FEV1 residuals explained by the
methacholine bronchial reactivity in this study, compared
to an earlier study in asthmatics (33), may be due to
dierent analysing methods. The earlier study did not
control for the FEV1/VC ratio and this might have
influenced results significantly. Controlling for the FEV1/
VC ratio in studies analysing bronchial reactivity and
baseline lung function is an important issue. This was
clearly shown in this study as we found no independent
relationship between bronchial reactivity to methacholine
and lung function, after controlling for FEV1/VC in
smokers with chronic bronchitis. The bronchial reactivity
to cigarette smoke had a closer relationship to baseline lung
function in smokers with chronic bronchitis and especially
in smokers with asthma compared to the methacholine
126 E. J. JENSEN ET AL.bronchial reactivity. Reasons for this may be a more
continous distribution of bronchial cigarette smoke reac-
tivity and, possibly, dierent modes of action on the
bronchial wall. Cigarette smoke probably mainly acts
through indirect mechanisms which may accelerate loss of
lung function. The dierent mode of action of cigarette
smoke and methacholine on the bronchial wall was
supported by the observation that both bronchial reactions
kept their significance after the addition of one of these
variables as an independent variable in the multivariate
analyses, in which the other was the dependent variable.
Not all asthmatic smokers develop chronic airflow
obstruction. The cigarette smoke bronchial reactivity may
aid in identifying those asthmatic smokers at risk of
developing airflow obstruction. To further study the nature
and possible importance of the bronhial response to
cigarette smoke, the inflammatory response, investigated
by means of studying the cellular and other changes in
broncho-alveolar lavage fluid after the smoking of a
cigarette, should be looked into and compared to the
responses from other compounds with an indirect mode of
action on the bronchial wall such as adenosin, allergens and
others.
The relationship between DFEV% and the presence of
respiratory symptoms indicated that the bronchial sensitiv-
ity to cigarette smoke might also have importance with
respect to development of airway symptoms from smoking.
The significant relationhip between S-IgE and DFEV%
was seen in non-asthmatic smokers. The relationship
persisted after controlling for other variables that might
influence DFEV% and therefore S-IgE had an independent
relationship to the bronchial sensitivity to cigarette smoke.
The reason why we found no such relationship in asthmatic
smokers was probably the greater variation in the S-IgE in
asthmatics and the small population of asthmatic smokers.
The relationship between S-IgE and smoking history was
in accordance with an earlier report (34) and indicates that
smoking aects the level of S-IgE per se. Whether this
indicates the development of an atopic predisposition
caused smoking in some smokers is not known, and the
mechanisms by which S-IgE influences the bronchial
reactivity to cigarette smoke is also unknown. DFEV%
was only weakly related to the blood eosinophil count and
the mechanism by which the blood eosinophil count
influences the bronchial sensitivity to cigarette smoke is
unknown. The lack of association between S-IgE and the
blood eosinophil count indicated that S-IgE and the blood
eosinophil count might influence the bronchial reactivity to
cigarette smoke dierently.
The independency between DFEV% and the total blood
leucocyte count might be caused by a large variation in
blood counts. It also might indicate that the bronchial
reactivity to inhaled cigarette smoke was independent of the
inflammation present in the airways in most smokers.
The relationship between DFEV% and baseline lung
function, respiratory symptoms, S-IgE and the blood
eosinophil count, indicated that the bronchial reactivity to
inhaled cigarette smoke might be useful in the investigation
of how smoking aects the bronchial mucosa in smokers in
general and especially in smokers with asthma.References
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